Moderna (MRNA) said that the two-season Phase 3 study evaluating the efficacy, safety and immunogenicity of Moderna’s trivalent vaccine against ...

It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...

Earnings: Discover insights into revenue shifts, cost reductions, 2027 product goals, RSV market strategies, and its broader ...

Moderna shares recovered from an early dip premarket despite the biotech's quarterly loss, as fading demand for its Covid-19 vaccine hurts sales. The company reported a net loss of $1.1 billion, or $2 ...

Among the handful of drugmakers to advance a successful COVID-19 vaccine in 2020, Moderna—whose mRNA shot Spikevax was also ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 ...

Massachusetts-based Moderna will likely be the first to manufacture a bird flu vaccine, backed by hundreds of millions in government funding. The biopharmaceutical giant is developing the vaccine ...

The study included vaccine candidates against H5 and ... impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly ...

Welcome to the Moderna fourth quarter 2024 conference call. At this time, all participants are in a listen-only mode. After ...

For more information about Moderna ... and potential for up to 17 participating countries to order COVID-19 vaccines from Moderna over a four-year period; and healthcare provider preferences ...

"Diversity of supply and availability of vaccine formats such as pre-filled syringes ... the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit ...